XNAS · Healthcare · Biotechnology
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.43 | -0.33 | +23.26% | $110,000 | ✅ Beat | +2.22% | -1.48% | — |
| 2026-03-12 | Q4 2025 | -0.38 | 0.26 | +168.42% | $30.9M | ✅ Beat | -1.09% | +5.94% | -5.71% |
| 2025-11-10 |
| Q3 2025 |
| -0.41 |
| -0.40 |
| +2.44% |
| $861,000 |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.51 | -0.50 | +1.96% | $836,000 | ✅ Beat | -2.21% | -6.25% | -3.68% |
| 2025-03-31 | Q4 2024 | -0.43 | -0.43 | +0.00% | $253,000 | ➖ Inline | -24.30% | -33.88% | -30.61% |
| 2024-08-12 | Q2 2024 | -0.39 | -0.45 | -15.38% | $778,000 | ❌ Miss | -2.46% | +4.58% | -6.87% |
| 2024-05-13 | Q1 2024 | -0.41 | -0.38 | +7.32% | $620,000 | ✅ Beat | +13.04% | +13.70% | +72.61% |
| 2024-03-27 | Q4 2023 | -0.38 | -0.37 | +2.63% | $262,000 | ✅ Beat | — | — | — |
Showing last 8 quarters.